PL2124547T3 - Sposób leczenia nowotworu - Google Patents

Sposób leczenia nowotworu

Info

Publication number
PL2124547T3
PL2124547T3 PL08729939T PL08729939T PL2124547T3 PL 2124547 T3 PL2124547 T3 PL 2124547T3 PL 08729939 T PL08729939 T PL 08729939T PL 08729939 T PL08729939 T PL 08729939T PL 2124547 T3 PL2124547 T3 PL 2124547T3
Authority
PL
Poland
Prior art keywords
treatment method
cancer treatment
cancer
treatment
Prior art date
Application number
PL08729939T
Other languages
English (en)
Inventor
Connie Lynn Erickson-Miller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2124547(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2124547T3 publication Critical patent/PL2124547T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08729939T 2007-02-16 2008-02-15 Sposób leczenia nowotworu PL2124547T3 (pl)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03
EP08729939.2A EP2124547B1 (en) 2007-02-16 2008-02-15 Cancer treatment method
PCT/US2008/054046 WO2008101141A2 (en) 2007-02-16 2008-02-15 Cancer treatment method

Publications (1)

Publication Number Publication Date
PL2124547T3 true PL2124547T3 (pl) 2018-08-31

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08729939T PL2124547T3 (pl) 2007-02-16 2008-02-15 Sposób leczenia nowotworu

Country Status (27)

Country Link
US (2) US20100075928A1 (pl)
EP (1) EP2124547B1 (pl)
JP (1) JP5511391B2 (pl)
KR (1) KR101447763B1 (pl)
CN (1) CN101662937B (pl)
AR (1) AR065348A1 (pl)
AU (1) AU2008216106B9 (pl)
BR (1) BRPI0807940B8 (pl)
CA (1) CA2678358C (pl)
CR (1) CR10997A (pl)
DK (1) DK2124547T3 (pl)
EA (1) EA017715B1 (pl)
ES (1) ES2675070T3 (pl)
HU (1) HUE038563T2 (pl)
IL (2) IL200319A (pl)
MA (1) MA31202B1 (pl)
MX (1) MX2009008822A (pl)
NZ (1) NZ579068A (pl)
PE (1) PE20081784A1 (pl)
PL (1) PL2124547T3 (pl)
PT (1) PT2124547T (pl)
SI (1) SI2124547T1 (pl)
TR (1) TR201809010T4 (pl)
TW (1) TW200906393A (pl)
UY (1) UY30915A1 (pl)
WO (1) WO2008101141A2 (pl)
ZA (1) ZA200905532B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CN101888841B (zh) * 2007-10-09 2012-09-26 宾夕法尼亚大学理事会 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞
US8609693B2 (en) 2009-05-29 2013-12-17 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
CN103079551A (zh) * 2010-09-01 2013-05-01 诺华有限公司 Hdac抑制剂与血小板减少症药物的组合
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
PL3452053T3 (pl) * 2016-05-06 2023-05-08 Taris Biomedical Llc Sposób leczenia urotelialnego nowotworu złośliwego dolnych dróg
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
CA2380206A1 (en) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
AU783238B2 (en) * 1999-11-10 2005-10-06 Innatus Corporation Method and system to remove cytokine inhibitor in patients
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6887890B2 (en) * 2000-05-30 2005-05-03 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
ATE292640T1 (de) * 2000-05-31 2005-04-15 Genzyme Corp Therapeutische verbindungen gegen eierstockkrebs
WO2002056912A2 (en) * 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
US20040063764A1 (en) 2001-01-26 2004-04-01 Hiroshi Takemoto Halogen compounds having thrombopoietin receptor agonism
EP1357116A4 (en) 2001-02-02 2005-06-01 Yamanouchi Pharma Co Ltd 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
JP2005510471A (ja) * 2001-09-24 2005-04-21 トスク インコーポレーティッド 減少した毒性のシスプラチン製剤及びそれを使用する方法
CA2472711C (en) 2002-01-18 2012-03-20 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or salt thereof
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
AU2003268687A1 (en) * 2002-09-30 2004-04-19 Yamanouchi Pharmaceutical Co., Ltd. Novel salt of 2-acylaminothiazole derivative
JP4895807B2 (ja) 2003-04-29 2012-03-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 変性疾患／損傷の治療方法
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2006047344A1 (en) * 2004-10-25 2006-05-04 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
JP2009519352A (ja) 2005-11-23 2009-05-14 リガンド・ファーマシューティカルズ・インコーポレイテッド トロンボポエチン活性調節化合物および方法
MX2008011666A (es) 2006-03-15 2008-10-17 Ligand Pharm Inc Sintesis de compuestos que modulan la actividad de la trombopoyetina.

Also Published As

Publication number Publication date
PE20081784A1 (es) 2009-01-25
MX2009008822A (es) 2009-08-28
HUE038563T2 (hu) 2018-10-29
BRPI0807940A2 (pt) 2013-07-30
AR065348A1 (es) 2009-06-03
MA31202B1 (fr) 2010-02-01
US20100075928A1 (en) 2010-03-25
CA2678358C (en) 2015-12-08
UY30915A1 (es) 2008-09-02
CN101662937A (zh) 2010-03-03
KR101447763B1 (ko) 2014-10-07
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
ES2675070T3 (es) 2018-07-06
CN101662937B (zh) 2014-03-12
PT2124547T (pt) 2018-07-04
EA200970776A1 (ru) 2010-02-26
IL200319A0 (en) 2010-04-29
EP2124547A2 (en) 2009-12-02
EP2124547B1 (en) 2018-03-28
BRPI0807940B8 (pt) 2021-05-25
IL238394B (en) 2018-05-31
WO2008101141A3 (en) 2008-10-16
NZ579068A (en) 2012-05-25
EA017715B1 (ru) 2013-02-28
CR10997A (es) 2009-10-16
IL200319A (en) 2015-05-31
AU2008216106B2 (en) 2013-07-11
BRPI0807940B1 (pt) 2020-10-27
JP5511391B2 (ja) 2014-06-04
TR201809010T4 (tr) 2018-07-23
IL238394A0 (en) 2015-06-30
EP2124547A4 (en) 2010-05-05
CA2678358A1 (en) 2008-08-21
TW200906393A (en) 2009-02-16
ZA200905532B (en) 2010-04-28
WO2008101141A2 (en) 2008-08-21
DK2124547T3 (en) 2018-07-16
SI2124547T1 (en) 2018-08-31
AU2008216106B9 (en) 2013-09-05
AU2008216106A1 (en) 2008-08-21
JP2010519221A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
BRPI0810206A2 (pt) Método de tratar câncer
EP2310006A4 (en) TREATMENT OF CANCER
HK1148906A1 (en) Compositions and methods for cancer treatment
IL212348A0 (en) Treatment method
GB0714363D0 (en) Treatment apparatus
HK1175476A1 (en) Cancer treatment
ZA200807934B (en) Cancer treatments
HK1137158A1 (en) Formulations for cancer treatment
EP2125002A4 (en) TREATMENT OF SKIN CANCER
EP1991230A4 (en) METHOD FOR THE TREATMENT OF CANCER
IL238394A0 (en) Cancer treatment method
GB0711342D0 (en) Well treatment
HK1139856A1 (en) Methods for treating acute pain
EP2144888A4 (en) METHODS OF TREATING CANCER
GB0804496D0 (en) Treating cancer
EP2088862A4 (en) METHOD OF TREATING CANCER
GB0718684D0 (en) Treatment method
EP2068911A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP2182884A4 (en) TREATMENT APPARATUS
GB0716784D0 (en) Well treatment
HK1225304A1 (zh) 治療骨癌
GB0707556D0 (en) Treatment for cancer
GB0809046D0 (en) Cancer treatment
EP2214485A4 (en) METHOD FOR THE TREATMENT OF CANCER
GB0710871D0 (en) Cancer treatment